Jade Biosciences, Inc. (JBIO) — Financial statements
Income statement, balance sheet, and cash flow for Jade Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.28↑193.8% | 0.10↑41.2% | 0.07↑353.3% | 0.02 | |
| Gross Profit | 0.00↑100.0% | -0.28↓193.8% | -0.10↓41.2% | -0.07↓353.3% | -0.02 | |
| Operating Expenses | ||||||
| R&D Expenses | 93↑75.1% | 53↓17.2% | 64↑66.3% | 39↑157.7% | 15 | |
| General & Administrative Expenses | 20 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 20↓3.3% | 21↑23.6% | 17↑17.5% | 15↑81.4% | 8 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 114↑52.8% | 74↓8.6% | 81↑52.9% | 53↑131.1% | 23 | |
| Total Costs & Expenses | 114↑52.2% | 75↓8.4% | 81↑52.9% | 53↑131.2% | 23 | |
| Operating Results | ||||||
| Operating Income | -114↓52.2% | -75↑8.4% | -81↓52.9% | -53↓131.2% | -23 | |
| Depreciation & Amortization | 0.03↓90.8% | 0.28↑193.8% | 0.10↑41.2% | 0.07↑353.3% | 0.02 | |
| EBITDA | -114↓63.8% | -69↑8.1% | -75↓46.6% | -51↓124.1% | -23 | |
| EBIT | -114↓63.2% | -70↑7.8% | -75↓46.6% | -51↓124.2% | -23 | |
| Interest & Other Income | ||||||
| Net Interest Income | 8↑54.3% | 5↓15.2% | 6↑224.9% | 2↑2715.4% | 0.07 | |
| Interest Income | 8↑54.3% | 5↓15.2% | 6↑224.9% | 2↑2715.4% | 0.07 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -5↑15.5% | -6↓239.5% | -2↓2724.2% | -0.06 | |
| Other Income / Expenses | -14↓374.9% | 5↓15.5% | 6↑239.5% | 2↑2724.2% | 0.06 | |
| Income Before Tax | -127↓83.0% | -70↑7.8% | -75↓46.6% | -51↓124.2% | -23 | |
| Income Tax Expense | 0.06↑5.5% | 0.06↓1.8% | 0.06↑124.0% | 0.03↑733.3% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -127↓83.0% | -70↑7.8% | -76↓46.6% | -52↓124.3% | -23 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -127↓83.0% | -70↑7.8% | -76↓46.6% | -52↓124.3% | -23 | |
| Bottom-Line Net Income | -127↓83.0% | -70↑7.8% | -76↓46.6% | -52↓124.1% | -23 | |
| EPS (Basic) | -4.06↑95.2% | -85.26↑15.1% | -100.38↓36.3% | -73.67↓123.5% | -32.96 | |
| EPS (Diluted) | -4.06↑95.2% | -85.26↑15.1% | -100.38↓36.3% | -73.67↓123.5% | -32.96 | |
| Weighted Average Shares | 31↑3740.1% | 0.82↑8.5% | 0.75↑7.6% | 0.70↑0.3% | 0.70 | |
| Weighted Average Diluted Shares | 31↑3740.1% | 0.82↑8.5% | 0.75↑7.6% | 0.70↑0.3% | 0.70 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.